Birchview Fund

Monteris Medical, Inc. is a medical device company specializing in the development and marketing of innovative technologies for the treatment of brain diseases. Founded in 1999 and based in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company focuses on minimally-invasive, MRI-guided, and robotically controlled neurosurgical procedures. Its flagship product, the NeuroBlate System, utilizes focused laser energy to safely ablate pathological brain lesions, such as tumors, while minimizing damage to surrounding healthy tissue. Monteris Medical also provides various stereotactic anchoring devices and stabilization systems for enhanced precision during image-guided procedures. The company markets its products directly to neurosurgeons in the United States, aiming to improve surgical outcomes through advanced technology.

Ogee is a luxury organic skincare brand founded in 2014 and headquartered in Burlington, Vermont. The company produces a range of skin‑care products—including lip care, moisturizers, serums, cleansers, and gift sets—using high‑quality natural and organic ingredients. Its formulations are certified by NSF for personal‑care products and incorporate American‑grown, cold‑pressed jojoba oil and other scientifically supported ingredients. Ogee sells its products through retailers and online channels, emphasizing ethical sourcing, fair business practices, and sustainability.

Monteris Medical, Inc. is a medical device company specializing in the development and marketing of innovative technologies for the treatment of brain diseases. Founded in 1999 and based in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company focuses on minimally-invasive, MRI-guided, and robotically controlled neurosurgical procedures. Its flagship product, the NeuroBlate System, utilizes focused laser energy to safely ablate pathological brain lesions, such as tumors, while minimizing damage to surrounding healthy tissue. Monteris Medical also provides various stereotactic anchoring devices and stabilization systems for enhanced precision during image-guided procedures. The company markets its products directly to neurosurgeons in the United States, aiming to improve surgical outcomes through advanced technology.

ContraFect Corporation is a clinical-stage biotechnology company based in Yonkers, New York, dedicated to developing innovative therapies for life-threatening and drug-resistant infectious diseases. Founded in 2008, the company focuses on creating therapeutic protein and antibody products, primarily using its proprietary lysin and monoclonal antibody platforms. Its lead candidate, CF-301, is an investigational lysin currently in Phase III trials for treating staphylococcus aureus bacteremia, including infections caused by methicillin-resistant strains. Additionally, ContraFect is advancing CF-296, which targets invasive staph aureus infections related to biofilms and osteomyelitis, and CF-370, aimed at gram-negative infections such as those caused by pseudomonas aeruginosa. The company also collaborates with The Rockefeller University to discover new lysin candidates targeting gram-negative pathogens and has initiated an expanded access program to provide exebacase for persistent bacteremia in COVID-19 patients.

Aspira Women's Health is a company dedicated to developing and commercializing diagnostic tests specifically for gynecologic oncology and women's health. Founded in 1993 and based in Austin, Texas, the company focuses on innovative testing solutions that address critical needs in women’s health. Its flagship product, OVA1 plus, combines two FDA-cleared tests to assess the risk of ovarian malignancy in women with adnexal masses. Additionally, Aspira offers OvaSuite, a portfolio of blood tests utilizing proprietary algorithms to evaluate patient risk, and OvaWatch, designed to help assess ovarian cancer risk in women with pelvic masses. By providing advanced diagnostic tools, Aspira Women's Health aims to enable healthcare providers to stratify risk, facilitate early detection, and improve treatment outcomes for women facing gynecologic health challenges.